Skip to main content

Allergy Program News

Experts from CHOP’s Allergy Program are recognized as global leaders in the management of allergic conditions and have helped formulate many of the national guidelines used by physicians around the world.

Contact us

In the Journals: Nirsevimab

Jan 18, 2024

Find out about the results of a prospective, placebo-controlled trial in 8,058 healthy infants that served as the basis for licensure of nirsevimab.

Jump back to top